Biopharma Firm Applies to Produce Large Quantities of Controlled Meds
Published Date: 8/11/2025
Notice
Summary
Biopharmaceutical Research Company wants to get official approval to make large amounts of certain controlled substances. This affects anyone tracking or regulating these drugs and could speed up research and development. Keep an eye out for updates on approval timing and any related fees.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 1 costs, 1 mixed.
Application to Bulk-Manufacture Controlled Drugs
Biopharmaceutical Research Company has applied to be registered as a bulk manufacturer of basic classes of controlled substances. This affects people and organizations that track or regulate these drugs and could speed up research and development.
Watch for Approval Timing and Fees
The notice advises stakeholders to watch for updates on approval timing and any related fees. If you are an applicant, regulator, or otherwise involved with these drugs, future notices may announce when approval happens and whether fees apply.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-19538, Bulk Manufacturer of Controlled Substances Application: Cambridge Isotope Laboratories, Inc.
Cambridge Isotope Laboratories wants to make a lot of a special drug called Tetrahydrocannabinols for testing purposes. People who already make or use this drug can share their thoughts by December 23, 2026, and ask for a hearing by November 23, 2026. This move could help scientists get better testing materials without changing how the drug is used.
2026-19540, Importer of Controlled Substances Application: Fisher Clinical Services, Inc. (I)
Fisher Clinical Services, Inc. wants to become an official importer of certain controlled substances like marijuana and its extracts. This affects companies involved in drug manufacturing and importation, who can comment or request a hearing by October 26, 2026. No direct costs are mentioned, but this move could impact how these substances enter the U.S. market.
2026-19542, Bulk Manufacturer of Controlled Substances Application: Cayman Chemical Company
Cayman Chemical Company wants to become an official bulk maker of some powerful controlled substances, mostly in Schedule I. This means they’ll be able to produce these drugs in large amounts for research or medical use. If you have thoughts or objections, you’ve got until November 23, 2026, to speak up online—no fees or money changes yet, just a chance to weigh in!
Previous / Next Documents
Previous: 2025-15161, Bulk Manufacturer of Controlled Substances Application: Chattem Chemicals
Chattem Chemicals wants to get official approval to make large amounts of certain controlled substances. This affects anyone involved in drug manufacturing and regulation, as it could change who supplies these important chemicals. Keep an eye out for updates on approvals and any new rules that might come with this change.
Next: 2025-15164, Notice of Public Hearing and Request for Comments on the Fair Market Value and Maximum Economic Recovery for the Little Eccles Coal Lease by Application, UTU-92226, in Emery County, Utah
The Bureau of Land Management wants your thoughts on how much the coal in the Little Eccles lease in Emery County, Utah, is really worth and how much can be profitably mined. This affects local communities, coal companies, and anyone interested in land use and energy resources. Speak up soon—your comments could shape the lease’s future value and mining plans!